IRLAB Therapeutics (IRLAB-A.ST)

Executive Summary

IRLAB Therapeutics is a Swedish biopharmaceutical company specializing in the discovery and development of novel drugs for central nervous system (CNS) disorders, particularly Parkinson's disease. The company leverages its proprietary Integrative Screening Process (ISP), a systems pharmacology platform that integrates extensive preclinical data to identify and optimize drug candidates efficiently. IRLAB's lead pipeline includes mesdopetam, a dopamine D3 receptor antagonist targeting Parkinson's disease psychosis (PDP), and pirepemat, a dopamine D1/D5 receptor agonist aimed at improving balance and gait in Parkinson's patients. Both candidates have progressed to Phase IIb clinical trials, with mesdopetam demonstrating positive top-line results in early 2026. The company also has earlier-stage assets targeting other CNS indications. Despite being pre-revenue and pre-clinical by stage, IRLAB's platform and focused strategy position it as a potential leader in Parkinson's therapeutics. However, execution risk remains high pending regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026Phase IIb top-line data for pirepemat in Parkinson's disease70% success
• Q4 2026Initiation of Phase II trial for next-generation ISP-derived candidate50% success
• Q4 2026Potential partnership or licensing deal for mesdopetam40% success